News
GRFS
6.48
+2.86%
0.18
Grifols Achieves Results From Phase 4 Study Of Fanhdi In Patients With Von Willebrand Disease
Benzinga · 2d ago
Weekly Report: what happened at GRFS last week (0415-0419)?
Weekly Report · 2d ago
Grifols SA’s Related Party Transactions: Navigating Conflicts of Interest and Investor Concerns
Grifols SA (GRFS) has disclosed a new risk, in the Debt & Financing category. The company engages in transactions with related parties, which raises concerns about potential conflicts of interest. Wall Street has a Strong Buy consensus rating on GRFS stock based on 3 buys.
TipRanks · 3d ago
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
Grifols celebrated the 50th anniversary of its flagship site in Clayton, N.C. Today. The company is a leading manufacturer of plasma-derived medicines. Grifols has saved the lives of millions of patients since its inception. The company's production of plasma has saved millions of lives.
Barchart · 6d ago
Grifols reportedly looking to appoint independent directors
Spanish drugmaker Grifols reportedly looking to appoint independent directors. Short-seller Gotham Research accused the company of accounting irregularities in January. The company has been criticized for its accounting practices. Grifol's CEO says appointing independent directors will help improve the company's governance.
Seeking Alpha · 04/15 15:37
Weekly Report: what happened at GRFS last week (0408-0412)?
Weekly Report · 04/15 09:24
ATUS, ATHE and GRFS among pre-market losers
On the Move ATUS, ATHE and GRFS among pre-market losers. Aptevo Therapeutics (APVO) -55% on pricing public offering. Carmax (KMX) -9% after Q4 earnings release. Altice USA, Inc. (ATUS) and Grifols SA (GRFS) in the red.
Seeking Alpha · 04/11 12:16
CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Shares of CarMax, Inc. Fell sharply in today’s pre-market trading after the company reported lower-than-expected fourth-quarter earnings. CarMax shares dipped 9.1% to $72.06 in pre- market trading. The Lovesac Company shares fell 13% after reporting worse- than-expected results. The Dow futures fell over 150 points on Thursday.
Benzinga · 04/11 12:03
Analysts Expect 15% Upside For KOMP
NASDAQ · 04/10 14:52
Deals of the day-Mergers and acquisitions
Spanish drug maker Grifols plans to meet its debt payments in 2025. Italy's Italgas has made a preliminary offer worth 4-5 billion euros for 2i Rete Gas. U.S. Rare-earths producer MP Materials says Gina Rinehart's mining firm has taken a stake in the company.
Reuters · 04/10 09:43
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
NASDAQ · 04/09 10:20
UPDATE 1-Aviva completes takeover of AIG's UK life insurance business
British insurer Aviva completes takeover of AIG's UK life insurance business. Aviva announced the deal in September. The company is buying the unit from Corebridge Financial, majority-owned by AIG. It is the largest takeover under Aviva CEO Amanda Blanc to date.
Reuters · 04/09 06:35
BRIEF-International Medical Industries Announces Partnership With Grifols For Enhanced Medication Safety
International Medical Industries Announces Partnership With Grifols for Enhanced Medication Safety. Company says it is working with KIRO to create a new form of packaging for pharmaceuticals. The company is part of International Medical Industries group of companies. Â  
Reuters · 04/08 14:59
European losers of higher financing costs - JPMorgan
J.P.Morgan analysts published a list of European companies that would suffer due to higher financing costs. According to a Global Markets Strategy report, if bond yields move further up, the market will weaken like it did last summer. The report published a basket of highly leveraged companies that could be the European losers.
Seeking Alpha · 04/08 13:41
Weekly Report: what happened at GRFS last week (0401-0405)?
Weekly Report · 04/08 09:26
Grifols Achieves Milestone In Transfusion Medicine With CE Mark For Procleix ArboPlex Assay
Grifols' in vitro nucleic acid test detects four types of arboviruses. The test helps mitigate the risk of transfusion-transmitted infections. Grifols is a leader in transfusion medicine. The company's in vitro test is the first of its kind.
Benzinga · 04/04 08:13
EUROPE RESEARCH ROUNDUP- Holcim, Renault, Wise
Analysts revise their ratings and price targets on several European companies. Holcim, Renault, Wise, and Wise among those with revised targets on Thursday. Ferrari cuts to equal weight from overweight, Barclays says. HSBC raises target price to EUR 57 from EUR 47 for Renault and Wise.
Reuters · 04/04 07:16
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
Grifols' new Procleix ArboPlex Assay has obtained the CE mark for an automated nucleic acid test specifically validated for screening blood donors to detect four major arboviruses. The test can detect chikungunya, dengue, West Nile and zika viruses.
Barchart · 04/04 03:00
Weekly Report: what happened at GRFS last week (0325-0329)?
Weekly Report · 04/01 09:25
Weekly Report: what happened at GRFS last week (0318-0322)?
Weekly Report · 03/25 09:26
More
Webull provides a variety of real-time GRFS stock news. You can receive the latest news about Grifols S A through multiple platforms. This information may help you make smarter investment decisions.
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.